Khiron Life Sciences Corp. Exclusive Medical Cannabis Sponsor at International Congress of Pain in Medellin, Colombia, May 10 -12

More than 1,000 physicians from every field of medicine expected to attend 27th annual conference

TORONTO, May 10, 2018 /CNW/ - Khiron Life Sciences Corp., a Canadian integrated medical cannabis company with its core operations in Colombia, is the exclusive sponsor of the medical cannabis module at the XXVII International Congress of Pain, being held at the Intercontinental Hotel in Medellin, Colombia, May 10 -12.

Khiron, one of the first companies in Colombia to be fully licensed to grow and cultivate cannabis for medicinal products for domestic distribution and export sale, will be demonstrating its medical cannabis e-learning modules at the Pain Congress in Medellin. The company will also be registering doctors interested in prescribing and dispensing Khiron's extract-based medical cannabis products to patients.

It is Khiron's mission to offer the safest medical cannabis option for patients by providing consistently safe products that have been developed based on extensive medical knowledge, research and innovation to improve patient quality of life.

A key element of Khiron's strategic development strategy is to focus on engaging and educating the medical community in Colombia and across Latin America about the benefits of medicinal cannabis. This sponsorship builds on the company's recent presentation of Colombia's first medical cannabis conference for more than 400 doctors and health professionals, and it's partnership with the Colombian Association of  Neurologists. Further, Khiron will be sponsoring and speaking at the upcoming CannaMexico World Summit 2018 taking place May 30-31, in partnership with former President Vicente Fox.

Alvaro Torres, President and CEO of Khiron, says, "Our patient-oriented approach includes working with healthcare professionals to offer patients safe, effective and affordable alternatives to existing pain medications, many of which are therapeutically ineffective or highly addictive in nature, or both."

"We aim to displace the opioid portion of the pharmaceutical market in Colombia and throughout Latin America by promoting medicinal cannabis as a safe, effective and affordable solution to meet the unmet medical needs of the population," Torres adds.

Colombia is estimated to have a medical cannabis market of 5.6 million patients, while the broader Latin American medical cannabis market has 68 million potential patients.

About Khiron Life Sciences Corp.
Khiron Life Sciences is a Canadian integrated medical cannabis company with its core operations in Colombia. Khiron combines leading international scientific expertise, agricultural advantages and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America. Khiron has received licences in Colombia for high- and low-tetrahydrocannabinol (THC) medical cannabis, and has received all licences required for the cultivation, production, domestic distribution, and international export of both THC and cannabidiol (CBD) medical cannabis.

Further information on the Company can be accessed through the link below:
www.khiron.ca

SOURCE Khiron Life Sciences Corp.

On behalf of the Board of Directors: Darren Collins, Chief Financial Officer, Direct: [phone], Email: [email protected]